BIOMAT Database Logo BIOMAT Database Logo

Prevention of meningococcal disease by group C polysaccharide vaccine. 1970

M S Artenstein, and R Gold, and J G Zimmerly, and F A Wyle, and H Schneider, and C Harkins

UI MeSH Term Description Entries
D008297 Male Males
D008589 Meningococcal Infections Infections with bacteria of the species NEISSERIA MENINGITIDIS. Meningococcal Septicemia,Infections, Meningococcal,Meningococcal Disease,Infection, Meningococcal,Meningococcal Diseases,Meningococcal Infection,Septicemia, Meningococcal
D008887 Military Medicine The practice of medicine as applied to special circumstances associated with military operations. Medicine, Military
D009345 Neisseria meningitidis A species of gram-negative, aerobic BACTERIA. It is a commensal and pathogen only of humans, and can be carried asymptomatically in the NASOPHARYNX. When found in cerebrospinal fluid it is the causative agent of cerebrospinal meningitis (MENINGITIS, MENINGOCOCCAL). It is also found in venereal discharges and blood. There are at least 13 serogroups based on antigenic differences in the capsular polysaccharides; the ones causing most meningitis infections being A, B, C, Y, and W-135. Each serogroup can be further classified by serotype, serosubtype, and immunotype. Diplokokkus intracellularis meningitidis,Meningococcus,Micrococcus intracellularis,Micrococcus meningitidis,Micrococcus meningitidis cerebrospinalis,Neisseria weichselbaumii
D011135 Polysaccharides, Bacterial Polysaccharides found in bacteria and in capsules thereof. Bacterial Polysaccharides
D002353 Carrier State The condition of harboring an infective organism without manifesting symptoms of infection. The organism must be readily transmissible to another susceptible host. Asymptomatic Carrier State,Asymptomatic Infection Carrier,Inapparent Infection Carrier,Presymptomatic Carrier State,Presymptomatic Infection Carrier,Super-spreader Carrier,Superspreader Carrier,Asymptomatic Carrier States,Asymptomatic Infection Carriers,Carrier State, Asymptomatic,Carrier State, Presymptomatic,Carrier States,Carrier, Super-spreader,Carrier, Superspreader,Carriers, Super-spreader,Carriers, Superspreader,Inapparent Infection Carriers,Infection Carrier, Asymptomatic,Infection Carrier, Inapparent,Infection Carrier, Presymptomatic,Presymptomatic Carrier States,Presymptomatic Infection Carriers,Super spreader Carrier,Super-spreader Carriers,Superspreader Carriers
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001428 Bacterial Vaccines Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease. Bacterial Vaccine,Bacterin,Vaccine, Bacterial,Vaccines, Bacterial
D012703 Serotyping Process of determining and distinguishing species of bacteria or viruses based on antigens they share. Serotypings

Related Publications

M S Artenstein, and R Gold, and J G Zimmerly, and F A Wyle, and H Schneider, and C Harkins
Vaccine potential of meningococcal group C polysaccharide-tetanus toxoid conjugate.
May 1983, The Journal of infection,
M S Artenstein, and R Gold, and J G Zimmerly, and F A Wyle, and H Schneider, and C Harkins
[Efficacy of the meningococcal vaccine from Group C capsular polysaccharide].
January 1997, Revista espanola de salud publica,
M S Artenstein, and R Gold, and J G Zimmerly, and F A Wyle, and H Schneider, and C Harkins
Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine.
December 2003, Infection,
M S Artenstein, and R Gold, and J G Zimmerly, and F A Wyle, and H Schneider, and C Harkins
[Effectiveness of an immunization campaign with group A and C meningococcal polysaccharide vaccine in controlling an outbreak of group C meningococcal disease].
June 2008, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi,
M S Artenstein, and R Gold, and J G Zimmerly, and F A Wyle, and H Schneider, and C Harkins
[Reactogenicity of a group A and C meningococcal polysaccharide bivalent vaccine].
July 1986, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
M S Artenstein, and R Gold, and J G Zimmerly, and F A Wyle, and H Schneider, and C Harkins
[Meningococcal C polysaccharide vaccine in Andalucia].
December 2000, Anales espanoles de pediatria,
M S Artenstein, and R Gold, and J G Zimmerly, and F A Wyle, and H Schneider, and C Harkins
[Evaluation on the safety of a group A + C meningococcal polysaccharide vaccine].
May 2007, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi,
M S Artenstein, and R Gold, and J G Zimmerly, and F A Wyle, and H Schneider, and C Harkins
Using the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease.
August 2008, Therapeutics and clinical risk management,
M S Artenstein, and R Gold, and J G Zimmerly, and F A Wyle, and H Schneider, and C Harkins
Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine.
February 2000, The Journal of infectious diseases,
M S Artenstein, and R Gold, and J G Zimmerly, and F A Wyle, and H Schneider, and C Harkins
Control of an outbreak of group C meningococcal meningitis with a polysaccharide vaccine.
September 1988, The Journal of infection,
Copied contents to your clipboard!